Faeth Therapeutics, Inc. (FTH)
| Market Cap | 723.53M +6,259.7% |
| Revenue (ttm) | n/a |
| Net Income | -195.53M |
| EPS | -82.46 |
| Shares Out | 25.84M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 328,188 |
| Open | 28.93 |
| Previous Close | 29.05 |
| Day's Range | 27.60 - 28.93 |
| 52-Week Range | 7.45 - 42.14 |
| Beta | -0.28 |
| Analysts | Strong Buy |
| Price Target | 56.67 (+102.39%) |
| Est. Earnings | Nov 13, 2026 |
About FTH
Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company’s pipeline includes SNS-102 and SNS-103, an active monoclonal antibody, which are in early ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for FTH stock is "Strong Buy." The 12-month stock price target is $56.67, which is an increase of 102.39% from the latest price.
News
Faeth Therapeutics names Karen Vousden to board of directors
Faeth Therapeutics (FTH) “announced that Karen Vousden, Ph.D., has been appointed to its Board of Directors, effective September 11, 2026. Dr. Vousden is a cancer biologist recognized for her work…
Faeth Therapeutics Appoints Karen Vousden, Ph.D., to Board of Directors
AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics, Inc. (Nasdaq: FTH), a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critic...
Faeth Therapeutics initiated with a Buy at Guggenheim ahead of de-risking data
As previously reported, Guggenheim initiated coverage of Faeth Therapeutics (FTH) with a Buy rating and $70 price target The firm, which views PIKTOR Phase 2 data in endometrial cancer due…
Faeth Therapeutics initiated with a Buy at Guggenheim
Guggenheim analyst Brad Canino initiated coverage of Faeth Therapeutics (FTH) with a Buy rating and $70 price target
Faeth Therapeutics assumed with a Buy at Lucid Capital
Lucid Capital assumed coverage of Faeth Therapeutics (FTH) with a Buy rating and $59 price target The firm sees current share levels as offering an attractive risk/reward into the year-end…
Faeth Therapeutics initiated with a Buy at TD Cowen
TD Cowen analyst Tara Bancroft initiated coverage of Faeth Therapeutics (FTH) with a Buy rating and no price target PIKTOR is validated by the recent success of Revtorpyk and the…
Faeth Therapeutics to Host Virtual KOL Event on Multi-Nodal Inhibition for the Treatment of Endometrial Cancer on October 6, 2026
AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announ...
Faeth Therapeutics to Participate in Upcoming September Investor Conferences
AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announ...
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics, Inc. (Nasdaq: FTH) today announced that the Compensation Committee of Faeth's Board of Directors granted three new employees options to purchase an ...
Faeth Therapeutics initiated with a Buy at Needham
Needham analyst Gil Blum initiated coverage of Faeth Therapeutics (FTH) with a Buy rating and $56 price target Piktor could emerge as a fast follower in PI3K/AKT/mTOR inhibition, leveraging multi-node...
Faeth Therapeutics granted Fast Track desingation for PIKTOR plus Paclitaxel
Faeth Therapeutics (FTH) announced that the U.S. Food and Drug Administration has granted Fast Track designation to the combination of sapanisertib and serabelisib with paclitaxel for the treatment of...
Faeth Therapeutics Announces FDA Grant of Fast Track Designation for PIKTOR Plus Paclitaxel in Biomarker-Selected Advanced Endometrial Cancer
AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announ...
Faeth Therapeutics appoints Tiwari, Biegler as Senior Vice Presidents
Faeth Therapeutics (FTH) announced the appointments of Deepak Tiwari as Senior Vice President, Technical Operations, and Matt Biegler as Senior Vice President, Investor Relations, as the company prepa...
Faeth Therapeutics Strengthens Executive Team with Senior Leadership Appointments
AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics, Inc. (Nasdaq: FTH) today announced the appointments of Deepak Tiwari as Senior Vice President, Technical Operations, and Matt Biegler as Senior Vice...
Faeth Therapeutics to Present PK/PD Modeling That Informed PIKTOR Dose Selection in Ongoing FTH-PIK-201 Trial at Upcoming Scientific Conference
AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing PIKTOR, an investigational all-oral, multi-node inhibitor of the PI3K/AKT/mTOR pathway, w...
Faeth Therapeutics management to meet with BTIG
Meeting to be held in Baltimore/Washington, DC on August 10 hosted by BTIG.
Faeth Therapeutics initiated with a Buy at JonesResearch
JonesResearch analyst Boris Peaker initiated coverage of Faeth Therapeutics (FTH) with a Buy rating and $55 price target The firm believes the company’s lead asset, Piktor, is potentially a best-in-cl...
Faeth Therapeutics reports Q2 EPS ($2.84) vs ($3.91) last year
“Our combination with Sensei Biotherapeutics marked an important milestone in the history of Faeth Therapeutics (FTH),” said Anand Parikh, Chief Executive Officer. “With the concurrent $200 million PI...
Faeth Therapeutics Reports Second Quarter 2026 Financial Results and Operational Updates
AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing PIKTOR, an investigational all-oral, multi-node inhibitor of the PI3K/AKT/mTOR pathway, t...
Faeth Therapeutics initiated with an Outperform at Raymond James
Raymond James initiated coverage of Faeth Therapeutics (FTH) with an Outperform rating and $56 price target The firm’s thesis centers on PIKTOR’s potential as an oral PI3Kalpha/mTOR inhibitor offering...
Faeth Therapeutics initiated with an Outperform at Oppenheimer
Oppenheimer initiated coverage of Faeth Therapeutics (FTH) with an Outperform rating and $60 price target Revtorpyk’s approval in PIK3CA-WT HR+/HER2- breast cancer in July supports PIKTOR’s probabilit...
Faeth Therapeutics initiated with an Outperform at Citizens
Citizens initiated coverage of Faeth Therapeutics (FTH) with an Outperform rating and $51 price target The company is focused on targeted therapies in oncology, the analyst tells investors in a…
Faeth Therapeutics, Inc trading resumes
15:41 EDT Faeth Therapeutics (FTH), Inc trading resumes
Faeth Therapeutics, Inc trading halted, volatility trading pause
15:31 EDT Faeth Therapeutics (FTH), Inc trading halted, volatility trading pause
Faeth Therapeutics initiated with an Outperform at Baird
Baird analyst Jack Allen initiated coverage of Faeth Therapeutics (FTH) with an Outperform rating and $57 price target Faeth is built around Piktor, an oral, multi-node approach to inhibiting the…